Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gitlab Inc (GTLB) vs Smith & Nephew plc (SNN) Price & Performance

Gitlab IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Gitlab Inc vs Smith & Nephew plc — how do they compare? Gitlab Inc trades at $55.07 (market cap $8.92B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Smith & Nephew plc for 121 Days on average.

GTLBSNN
Market Cap
$8.92B$11.10B
Volume
4,716,8931,051,703
Sector
TechnologyHealth
52-Week High
$53.56$37.17
52-Week Low
$19.42$26.42
Typical Hold Time
62 Days121 Days
Enterprise Value
$7.66B$14.13B
Dividend Yield
—2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gitlab Inc

GitLab (GTLB) trades at $55.09, up 5.96% today and near its 52-week high, with strong technical momentum. The company shows impressive revenue growth, reaching $759M in 2025, though it remains unprofitable with a net margin of -4.99%. Recent Q2 2026 earnings beat expectations with EPS of $0.24 versus $0.18 expected, driven by AI product traction and sales momentum. Analyst sentiment is mixed with a Hold consensus but positive news flow highlights AI-driven demand and raised guidance.

Outlook: GTLB benefits from AI integration in DevSecOps and strong execution, but high valuation (P/E 521) and persistent losses pose risks. Investment case hinges on sustained revenue growth and path to profitability. Key risks include competitive pressure and reliance on AI adoption trends.

Smith & Nephew plc

Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.

The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GTLB
100% Buy0% Sell
Avg holding period · 62 Days
SNN

No sentiment data available yet.

About Gitlab Inc

GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.

Read more on GTLB →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →